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to 5,607 GBP/QALY. Adding SNS before SR corresponded to a QALY gain of 0.62, 
with ICUR 14,357 GBP/QALY. The most cost-effective treatment pathway for WSD 
patients was NASHA/Dx followed by SNS, with a maximum ICUR of 5,928 GBP/
QALY vs the other treatment pathways analysed. In comparison with treatment 
pathway excluding SNS, 0.55 QALY are gained. ConClusions: SNS is a relevant 
treatment for FI in patients who have failed conservative management. Including 
SNS into the treatment pathway for refractory FI may provide value-for-money 
in the UK NHS perspective.
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objeCtives: Implantable cardioverter-defibrillators (ICD) improve survival in 
heart failure patients with New York Heart Association Functional Classification 
(NYHA) class III/IV symptoms and a left ventricular ejection fraction (LVEF) of ≤ 35%. 
Therefore, the current clinical guidelines recommend the implantation of the ICD 
in all the patients that fulfill the above conditions. However, as the costs of the ICD 
devices are relatively high, the prophylactic implantation of ICDs as per the guide-
line is not particularly cost-effective. A previous study demonstrated that short-term 
variability of QT (STVQT) may in fact reflect the increased susceptibility to SCD in 
patients with DC since it was shown that patients with DC and HF had the highest 
STVQT. The objective of this study was to explore the cost–effectiveness of short-
term variability of QT (STVQT) as a biomarker for implanting ICDs as secondary 
prevention of SCDs in heart failure patients and assess the societal value (headroom) 
of a hypothetical perfect STVQT biomarker for risk assessment and subsequent 
treatment decision in implanting ICDs . Methods: The study uses a decision ana-
lytical model. Results: The use of the QT (STVQT) as a biomarker for implanting 
ICDs as secondary prevention of SCDs in heart failure patients is a cost-effective 
healthcare intervention. The headroom (societal willingness to pay multiplied by 
incremental quality-adjusted life years) available for the hypothetical perfect bio-
marker ranged from € 483 to € 3,868. ConClusions: The use of the QT (STVQT) as 
a biomarker for implanting ICDs is cost effective. Identification of patients with 
high-risk for SCD and implantation of ICDs only on those patients could potentially 
save substantial costs. However, further research of risk stratifying biomarkers test 
accuracy is needed to support and strengthen the results of this modeling study.
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objeCtives: A curative treatment for patients with Allergic Rhinitis (AR) is 
immunotherapy (IT). However, not all patients are susceptible for IT, and many 
patients currently receive this treatment without any effect. Component Resolved 
Diagnosis (CRD) is a technique that might help identifying susceptible patients 
for IT. This study aimed to evaluate the impact of diagnosing patients with AR 
with CRD on treatment prescription, costs and (health) outcomes compared 
to diagnosing patients with standard testing (Skin Prick Testing (SPT)) in the 
Netherlands. Methods: A literature search and interviews with experts were 
performed to structure a decision tree and to determine relevant parameters for 
the analysis. Parameter values were based on literature data; costs were retrieved 
from national databases. Primary outcomes were the incremental cost per addi-
tional full responder and the incremental cost per Quality Adjusted Life Year (QALY) 
over a time horizon of nine years. Results: Diagnosis through CRD increased the 
number of full responders to IT compared to diagnosing patients with SPT (13,239 
[95%CI; 10,039 – 16,868] vs 9,422 [95%CI; 7,384 – 11,891]). QALYs also increased more 
for patients on IT based on CRD compared to patients diagnosed with SPT (0.02734 
[95%CI; -0.0216 – 0.0338] vs 0.02362 [95%CI; 0.0201 – 0.0276]). Expected total costs per 
patient reduced when diagnosis took place with CRD, from € 7,555 [95%CI; € 7,496 
– € 7,618] to € 7,255 [95%CI; € 7,062 – 7,453]. The incremental cost per additional full 
responder and the incremental cost per Quality Adjusted Life Year (QALY) were 
€ -12,773 and € -80,667 respectively. The PSA showed that in 96.4% of the 10,000 simu-
lations CRD was dominant in both costs and additional full responders, and in 84.8% 
in both costs and additional QALYs. ConClusions: Using CRD in the diagnosis of 
patients with suspected AR seems to be both cost saving as improving treatment 
decisions and health outcomes.
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objeCtives: Cardiac resynchronization therapy (CRT) either via a pacing device 
(CRT-P) or a pacemaker-defibrillator device (CRT-D) is considered an effective treat-
ment for patients with congestive heart failure (CHF) and disturbances in heart 
rhythm (arrhythmias) having New York Heart Association (NYHA) class II, III and 
IV symptoms. However, due to the large numbers of patients, which do not get 
additional benefits from CRT-D, and also due to large costs of implementation and 
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objeCtives: Although self-administration “pen” devices offer certain advantages, 
their higher cost has prevented its wider dissemination in patients with diabe-
tes. The aim of this study was to determine their cost-effectiveness, compared 
to conventional vial and syringe, in adult patients in Colombia. Methods: We 
designed a cost-effectiveness Markov model, with annual cycles, five-year time 
horizon (with analysis at 3 and 10 years), 5% discount rate, and third party payer 
perspective (Colombian health system). Transition probabilities and utilities in 
quality adjusted life years (QALY) were obtained from a systematic review of the 
literature. Costs, in 2014 Colombian pesos (1 euro = 2,660 COP), were obtained 
locally from different sources (following the methodology proposed by IETS, the 
Colombian HTA agency). Cost-effectiveness threshold was three times per capita 
GDP (equivalent to € 17,547 per QALY). Results: The total cost of treating a patient 
with a syringe and vial over five years would be € 1,002, while the use of pen device 
would represent € 1,226. In the same period, the patient would gain 3.1709 and 
3.1849 QALY, respectively, representing an incremental cost effectiveness ratio 
(ICER) of € 15,302 per additional QALY gained. By extending the time horizon, 
the ICER lowers (€ 10,424 in 10 years). Different discount rates, from 0 to 12%, do 
not substantially alter the results. With a price reduction of 31% the pen device 
reaches the threshold of 1 per capita GDP. In the sensitivity analysis, the variables 
related to hypoglycemia (frequency and costs of treatment) are the ones that 
most modify the results. Cost-effectiveness, however, is maintained under dif-
ferent scenarios. ConClusions: Given the assumptions and limitations of this 
model, the pen-like devices for self-administration of insulin are cost-effective, 
compared with administration by vial and disposable syringes, in adult patients 
with diabetes in the Colombian context.
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objeCtives: Transcatheter aortic valve replacement (TAVR) is an important new 
therapy approach for the treatment of severe aortic stenosis. Our objective was to 
identify and review the growing body of published cost-effectiveness analyses of 
TAVR, and to identify opportunities for future modeling and analyses in light of 
new clinical evidence. Methods: A systematic search in PubMed, Embase, and 
HTA agency databases and a grey search were conducted for the period from 2005 
through 2014 to identify studies examining the cost-effectiveness of aortic valve 
replacement using a transcatheter-based intervention. Searches, study selection, 
and data extraction were performed according to a predefined protocol. We only 
included studies on cost-effectiveness of TAVR compared with either medical 
management (MM) or surgery (SAVR). Appraised studies were analyzed using the 
CHEERS checklist. Results: Our search yielded n= 15 studies, comprising 13 distinct 
decision-analytic models set in six countries: Belgium, Brazil, Canada, Spain, United 
Kingdom, and U.S.A. Four of the models were developed by national HTA agencies 
or academic groups. In some cases, HTA reports differed from the published results. 
Study quality per CHEERs criteria was poor to excellent. n= 7 models compared TAVR 
to medical management, two to surgery, and n= 5 evaluated the cost-effectiveness 
of TAVR in comparison to both. n= 13 studies utilized efficacy data from PARTNER 
A and B. Only one study used patient-level data in an “along-the-trial” design. ICER 
in studies comparing TAVR to MM ranged from £12,600 to US$115,600 per QALYs. 
Compared with SAVR, ICER estimates ranged from TAVR dominating to being domi-
nated. ConClusions: Economic evaluations are lagging behind published clinical 
evidence. Future opportunities include economic evaluation of newer clinical trial 
data, long-term follow-up data from earlier studies, and more explicit evaluation of 
subsets of patient cohorts. Overall model quality and reporting of methods including 
data sources could be improved further.
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objeCtives: To evaluate the cost-utility of including sacral nerve stimulation (SNS) 
in different treatment pathways for refractory fecal incontinence (FI). Methods: 
The treatment pathways of two populations, with a surgically repairable sphincter 
defect (SD) and without (WSD), were modeled through a patient-level simulation 
model. Three comparators to SNS were included: sphincter repair (SR), NASHA/
Dx and percutaneous tibial nerve stimulation. Colostomy or conservative treat-
ment were modeled as last resort. Clinical data were based on a systematic lit-
erature review and expert opinion (EO). Resource use was based on EO, whilst 
cost data were based on hospital costs and national tariff lists (GBP 2015-16). The 
UK NHS perspective (threshold: 30,000 GBP/QALY) and a lifetime horizon were 
adopted. Results: For SD patients, the most effective treatment pathway was 
SNS followed by SR, however it was not cost-effective vs SR followed by SNS (ICUR 
= 44,562 GBP/QALY). Adding SNS after or before SR was cost-effective vs SR only. 
In case of SNS used after SR the gain in QALY was equal to 0.48, with ICUR equal 
